Outsource API manufacturing to India for lower costs, GMP-compliant quality, scalable production, and faster time-to-market for pharma companies.

AbbVie’s $100 billion splurge on domestic manufacturing and R&D is continuing to come into focus, this time with a $380 million investment in two new active pharmaceutical ingredient (API) manu | The ...

AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing ...

Just weeks after announcing a deal to sell its antibiotics manufacturing in the U.S. to Neopharma, India’s Dr. Reddy’s Laboratories says it will now unload its API manufacturing business in Jeedimetla ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast projects the global active pharmaceutical ingredient market to expand from ...

AbbVie invests $380m in North Chicago for API manufacturing, creating 300 jobs, boosting US R&D, and expanding domestic ...

EAST RUTHERFORD, N.J., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), ...

AbbVie is investing $380 million to build two new active pharmaceutical ingredient (API) manufacturing facilities at its ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...

The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031. Demand for biologics, biosimilars, and other biopharmaceuticals is growing at a ...